The analysis found no significant association between SGLT2 inhibitor use and the risk of all-cause dementia (odds ratio (OR): 1.37; 95% CI: 0.70-2.69), Alzheimer's (OR 1.99; 95% CI, 0.59-6.71), or even vascular dementia (OR 0.40; 95% CI, 0.09-1.85) when compared with control groups, which were predominantly placebo [3]. This evidence concerns the gene SLC5A2 and vascular dementia.